Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated PTCy-MILs for Relapsed Hematologic Malignancies
NCT02342613Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2015
- Primary completion
- Nov 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of activated PTCy-MILs in hematologic malignancy, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Feasibility of generating activated marrow infiltrating lymphocytes (MILs) at 90 days and Toxicity of PTCy-MILs at 90 days. Started May 2015; status: completed.
02
Drugs
activated PTCy-MILs
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02342613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342613.